Aravax Presents Additional Positive PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019
June 4, 2019, Melbourne, Victoria –Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma
Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, today reported additional data from a recently completed Phase 1 clinical trial of PVX108 immunotherapy at the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress taking place June 1 – 5 in Lisbon, Portugal. PVX108 is a peptide-based immunotherapy designed to safely induce immune tolerance to peanut allergens without the safety limitations of other approaches that expose patients to intact, allergenic protein that may cause allergic reactions or anaphylaxis during treatment.
Preliminary results from the trial were previously presented at the 2019 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in February 2019. The presentation at EAACI includes additional demographic data on the proportion of patients in the trial with prior anaphylactic responses to peanuts and/or current asthma, as well data demonstrating stable lung function following PVX108 administration. Sara Prickett, BSc, PhD, Chief Scientific Officer at Aravax presented the data today in an oral presentation titled: “PVX108 – A Peptide-Immunotherapy for Peanut Allergy Shows Exceptional Safety in Peanut-Allergic Adults (Abstract #2071) during Session LB OAS 03 (Advances in cellular immunology).